Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 20/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16677851 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742515 | 0.84 | HDAC3 (0.74) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729841 | 0.82 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL17025843 | 0.81 | HDAC3 (0.67) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742387 | 0.81 | HDAC3 (0.79) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742685 | 0.79 | HDAC6 (0.67) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742560 | 0.78 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729593 | 0.78 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729871 | 0.77 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL28067236 | 0.77 | HDAC3 (0.79) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENT (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | HDAC6, PKD1, PKD2 | HDAC3 17/4885HDAC1 4/4885HDAC2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.